Carnosine
17 benefits mapped to clinical evidence across supplements.
Dose per serving from products
170 products in our catalogue print how much Carnosine a serving holds.
Most common: 250 mg to 500 mg, 41% of 170 products.
| Dose per serving | Products |
|---|---|
| 10 mg or less | 4 |
| 10 mg to 25 mg | 10 |
| 25 mg to 50 mg | 32 |
| 50 mg to 100 mg | 25 |
| 100 mg to 250 mg | 16 |
| 250 mg to 500 mg | 69 |
| 500 mg to 1 g | 13 |
| over 1 g | 1 |
Dose per serving from research
27 study groups in 26 studies say how much Carnosine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 33% of 27 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 4 |
| 250 mg to 500 mg | 6 |
| 500 mg to 1 g | 8 |
| 1 g to 2.5 g | 9 |
Benefit Evidence
Acidosis buffer: +32%, -23%
Glucose control: -1.6 mmol/L
Exercise capacity: +23% TTE
Acidosis buffer: +32%, -23%
Glucose control: -1.6 mmol/L
Exercise capacity: +23% TTE
Research sources
Cell health (12)
- Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer
PubMed ID: 20104529
Polaprezinc reduced chemo/radiation oral mucositis and analgesic use—clinically meaningful epithelial protection.
- Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial
PubMed ID: 39215872
Increased tissue/systemic carnosine and detection of carnosine–aldehyde conjugate supports capacity for aldehyde scavenging/cellular protection (biomarker evidence).
- Effect of Oral carnosine supplementation on urinary TGF-β in diabetic nephropathy: a randomized controlled trial
PubMed ID: 34174842
Lowered urinary TGF‑β (renal injury biomarker) in diabetic nephropathy suggests organ‑level cellular protection.
- Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi-institutional randomized controlled trial
PubMed ID: 32984946
Reduced mucositis incidence implies protection of mucosal cells during chemotherapy.
- L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways
PubMed ID: 30592963
Marked reductions in caspase‑3 and MDA and increased Nrf2 indicate cellular/antiapoptotic protection.
- The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial
PubMed ID: 28744992
L‑carnosine in T1D nephropathy reduced albuminuria and tubular injury marker (alpha1‑microglobulin), indicating renal cellular protection.
- Zinc supplementation influences genomic stability biomarkers, antioxidant activity, and zinc transporter genes in an elderly Australian population with low zinc status
PubMed ID: 25755079
Zinc–carnosine reduced genomic instability (micronuclei/comet) in elderly—cellular/nuclear protection.
- Basal protrusion of ulcers induced by endoscopic submucosal dissection (ESD) during treatment with proton pump inhibitors, and the suppressive effects of polaprezinc
PubMed ID: 20698249
Large RCT: polaprezinc + PPI markedly improved ulcer healing and nearly eliminated ulcer‑base protrusion—strong mucosal/cellular protection signal.
- Comparison of the Efficacy of Polaprezinc Plus Proton Pump Inhibitor and Rebamipide Plus Proton Pump Inhibitor Treatments for Endoscopic Submucosal Dissection-induced Ulcers
PubMed ID: 32341237
Zinc–L‑carnosine (polaprezinc) promoted mucosal healing and is used for cellular/mucosal protection—trial supports safety and equivalence for healing.
- l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial
PubMed ID: 29420997
Oral L‑carnosine reduced AGEs and TNF‑α in T2D, directly supporting protection against glycation‑driven cellular damage.
- N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts
PubMed ID: 11390029
NAC eye drops improved lens clarity and function—consistent with protecting lens proteins from oxidative/glycation damage.
- Efficacy of N-acetylcarnosine in the treatment of cataracts
PubMed ID: 12001824
Randomized NAC topical trial improved objective lens measures, indicating protein/lens protection in vivo.
Brain health (11)
- A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia
PubMed ID: 23099060
Adjunctive L‑carnosine improved executive cognition (set‑shifting, perseveration) in schizophrenia—domain‑specific brain benefit.
- Cognitive and negative symptoms in schizophrenia with L-Carnosine adjuvant therapy - A randomized double-blind placebo-controlled study
PubMed ID: 36946070
No effect on negative symptoms but improved executive function (Trail B) in larger RCT.
- Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4
PubMed ID: 31319510
Preservation of cognitive measures and EEG in APOE4+ MCI supports brain‑protective effects.
- L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial
PubMed ID: 29427913
Adjunctive L‑carnosine improved negative and total symptoms in schizophrenia, indicating CNS effects.
- Anserine/Carnosine Supplementation Suppresses the Expression of the Inflammatory Chemokine CCL24 in Peripheral Blood Mononuclear Cells from Elderly People
PubMed ID: 29088099
Improved delayed verbal memory and lowered inflammatory chemokine in elderly—brain function relevance.
- L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study
PubMed ID: 28485008
Randomized double-blind trial: L-carnosine adjunct to fluvoxamine produced clinically meaningful additional reductions in OCD Y-BOCS scores.
- l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
PubMed ID: 29027815
Improved hyperactivity/noncompliance in autistic children indicates behavioral/brain function impact.
- Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial
PubMed ID: 39919936
Large RCT: oral carnosine improved cognitive processing speed/efficiency in younger adults—direct evidence for brain function enhancement.
- Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants
PubMed ID: 20224285
Adjunct multi‑antioxidant (includes carnosine) with donepezil reduced oxidative stress and produced modest cognitive benefits in AD.
- Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders
PubMed ID: 12585724
Double‑blind RCT in children with autism found statistically significant behavioral and receptive language improvements after L‑carnosine.
- Effect of Anserine/Carnosine Supplementation on Verbal Episodic Memory in Elderly People
PubMed ID: 26682691
Anserine/carnosine preserved episodic memory and brain perfusion in elderly—strong brain function support.
Antioxidant (10)
- L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways
PubMed ID: 30592963
Strong RCT in chemo patients showed marked reductions in oxidative markers (MDA) and raised Nrf2.
- A Clinical Trial about a Food Supplement Containing α-Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients
PubMed ID: 27801825
Multi‑ingredient trial (ALA + carnosine etc.) improved antioxidant enzyme markers (SOD/GSH‑Px) and MDA; carnosine contribution plausible but uncertain.
- Effects of α-Lipoic Acid, Carnosine, and Thiamine Supplementation in Obese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind Study
PubMed ID: 30311825
Combination ALA+carnosine+thiamine lowered oxidative stress (hydroperoxides) but multi‑ingredient limits attribution to carnosine alone.
- l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial
PubMed ID: 29420997
Direct RCT of L‑carnosine reduced AGEs and inflammatory/oxidative markers in T2D—strong direct antioxidant signal.
- N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts
PubMed ID: 11390029
Topical N‑acetylcarnosine (NAC) eye drops produced durable lens/vision improvements consistent with antioxidant/transglycation activity.
- Efficacy of N-acetylcarnosine in the treatment of cataracts
PubMed ID: 12001824
Randomized NAC eye‑drop trial showed objective lens and vision improvements consistent with antioxidant mechanism.
- Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops
PubMed ID: 15588519
NAC eye drops improved acuity and glare in older drivers; effect consistent with antioxidation in the lens.
- Zinc supplementation influences genomic stability biomarkers, antioxidant activity, and zinc transporter genes in an elderly Australian population with low zinc status
PubMed ID: 25755079
Zinc–carnosine RCT in elderly lowered DNA‑damage markers (micronuclei/comet), consistent with reduced oxidative/genotoxic stress.
- The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial
PubMed ID: 28744992
RCT in T1D nephropathy showed reduced MDA and increased total antioxidant capacity—direct antioxidant/oxidative stress benefit.
- Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial
PubMed ID: 39215872
Oral carnosine substantially raised systemic/tissue carnosine (an antioxidant); biomarker-level support but no clinical antioxidant endpoint.
Metabolism (9)
- A Clinical Trial about a Food Supplement Containing α-Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients
PubMed ID: 27801825
Multi‑ingredient supplement including L‑carnosine improved glycemic control and lipids in T2D; carnosine's individual contribution uncertain but metabolic endpoints improved.
- Effects of α-Lipoic Acid, Carnosine, and Thiamine Supplementation in Obese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind Study
PubMed ID: 30311825
Combination ALA+carnosine+thiamine in obese T2D lowered glucose and HbA1c and oxidative stress; multi‑ingredient trial but clear metabolic improvements.
- l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial
PubMed ID: 29420997
Direct double‑blind RCT of L‑carnosine in T2D showed significant reductions in fasting glucose, TG, AGEs and improved body composition—strong metabolic signal.
- A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial
PubMed ID: 38732615
Multi‑ingredient supplement (HMB + carnosine + others) improved lean mass, reduced VAT and inflammatory markers—beneficial metabolic effects in sarcopenic elderly.
- Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial
PubMed ID: 27040154
Double‑blind RCT of 2 g/day carnosine in overweight/obese adults attenuated worsening of insulin resistance and improved 2‑hr OGTT glucose—direct metabolic benefit.
- A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial
PubMed ID: 26406981
Multi‑ingredient supplement (cinnamon, chromium, carnosine) modestly reduced fasting glucose and increased lean mass in pre‑diabetic adults—metabolic improvement though attribution uncertain.
- The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial
PubMed ID: 28744992
L‑carnosine in children with T1D nephropathy lowered HbA1c and improved markers of renal injury—strong metabolic/glycemic benefit.
- Carnosine Supplementation Improves Serum Resistin Concentrations in Overweight or Obese Otherwise Healthy Adults: A Pilot Randomized Trial
PubMed ID: 30205427
Carnosine lowered resistin and trended to lower leptin in overweight/obese adults (pilot RCT).
- Carnosine supplementation improves glucose control in adults with pre-diabetes and type 2 diabetes: A randomised controlled trial
PubMed ID: 38172006
2 g/day carnosine reduced 90/120‑min OGTT glucose and total glucose AUC in prediabetes/T2D (RCT).
Immune support (7)
- Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi-institutional randomized controlled trial
PubMed ID: 32984946
Prophylactic zinc‑carnosine substantially reduced moderate oral mucositis after HSCT (mucosal/immune protection).
- Beneficial effect of polaprezinc on cardiac function post-myocardial infarction: A prospective and randomized clinical trial
PubMed ID: 30855449
Post‑MI polaprezinc lowered an inflammation index (IL‑6/max CPK) and raised serum zinc.
- L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways
PubMed ID: 30592963
Reduced TNF‑α and NF‑κB in chemo patients indicates immune/inflammatory modulation.
- Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial
PubMed ID: 28407007
Polaprezinc added to H.pylori therapy significantly raised eradication rates (immune/anti‑infective relevance).
- l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial
PubMed ID: 29420997
Oral L‑carnosine in T2D lowered TNF‑α and AGEs, indicating an anti‑inflammatory effect relevant to immune status.
- Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection
PubMed ID: 10215732
Zinc‑L‑carnosine (polaprezinc) significantly increased H. pylori eradication rates when added to triple therapy—clinically meaningful mucosal/antimicrobial support.
- A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial
PubMed ID: 38732615
Multi‑ingredient (includes carnosine) reduced TNF‑α/CRP and gut permeability markers in older sarcopenic adults, indicating anti‑inflammatory/immune‑modulating effects.
Memory (5)
- Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial
PubMed ID: 39919936
Large randomized trial: oral carnosine improved cognitive processing speed and several cognitive domain scores in younger adults—direct human evidence for cognitive benefit.
- Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants
PubMed ID: 20224285
Multi‑antioxidant formula (includes carnosine) added to donepezil produced modest cognitive benefit in AD patients—suggests possible memory support role.
- Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4
PubMed ID: 31319510
Anserine/carnosine preserved MMSE and global CDR in APOE4+ MCI subgroup (randomized trial).
- Effect of Anserine/Carnosine Supplementation on Verbal Episodic Memory in Elderly People
PubMed ID: 26682691
Anserine/carnosine supplementation preserved delayed verbal episodic memory and preserved posterior cingulate perfusion in elderly RCT.
- Anserine/Carnosine Supplementation Suppresses the Expression of the Inflammatory Chemokine CCL24 in Peripheral Blood Mononuclear Cells from Elderly People
PubMed ID: 29088099
Supplementation associated with preserved delayed verbal memory and reduced inflammatory chemokine in older adults.
Skin appearance (5)
- An urea, arginine and carnosine based cream (Ureadin Rx Db ISDIN) shows greater efficacy in the treatment of severe xerosis of the feet in Type 2 diabetic patients in comparison with glycerol-based emollient cream. A randomized, assessor-blinded, controlled trial
PubMed ID: 23009311
Urea+arginine+carnosine foot cream markedly improved foot skin dryness and patient-reported hydration vs standard emollient in Type 2 diabetes—clinically meaningful topical benefit.
- Efficacy of anti-aging products for periorbital wrinkles as measured by 3-D imaging
PubMed ID: 19735523
Split-face randomized cosmetic trials: topical carnosine-containing products reduced periorbital wrinkle roughness at 4 weeks—direct evidence for improved skin appearance.
- Neuroimmunomodulatory compound for sensitive skin care: in vitro and clinical assessment
PubMed ID: 18482014
Randomized double‑blind trial: cream combining L‑carnosine and Rhodiola improved TEWL and subjective skin comfort in sensitive skin.
- Use of a urea, arginine and carnosine cream versus a standard emollient glycerol cream for treatment of severe xerosis of the feet in patients with type 2 diabetes: a randomized, 8 month, assessor-blinded, controlled trial
PubMed ID: 25851453
Urea+arginine+carnosine cream produced sustained, clinically and instrumentally measured improvement in diabetic foot skin dryness over 8 months.
- Skin beautification with oral non-hydrolized versions of carnosine and carcinine: Effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging
PubMed ID: 21756141
Randomized human trial of stabilized carnosine formulation produced objective improvements in skin surface parameters and visual appearance over 3 months.
Muscle growth (4)
- Efficacy of N-acetylcarnosine in the treatment of cataracts
PubMed ID: 12001824
Randomized NAC trial supports lens protein protection via transglycation/antioxidant mechanisms.
- l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial
PubMed ID: 29420997
Reduction in circulating AGEs indicates systemic decrease in protein glycation processes after oral L‑carnosine.
- N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts
PubMed ID: 11390029
NAC eye‑drop RCTs improved lens protein clarity—direct evidence of protein protection in the lens.
- Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial
PubMed ID: 39215872
Study detected increased carnosine–aldehyde conjugates, indicating direct biochemical protein/aldehyde scavenging activity.
Eye health (4)
- N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population
PubMed ID: 19503764
N‑acetylcarnosine eye drops produced significant improvements in glare sensitivity and visual acuity over 9 months in older adults—strong clinical vision benefit.
- N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts
PubMed ID: 11390029
Randomized topical NAC produced substantial and durable improvements in lens transmissivity, visual acuity and glare in cataract patients.
- Efficacy of N-acetylcarnosine in the treatment of cataracts
PubMed ID: 12001824
Placebo‑controlled NAC eye‑drop RCT showed objective lens and vision benefits at 6 months.
- Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops
PubMed ID: 15588519
Double‑blind RCT in older drivers including cataract patients showed NAC eye drops significantly improved acuity and glare at 4 months.
Healthy aging (4)
- N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts
PubMed ID: 11390029
NAC eye drops improved lens clarity and vision in older patients—clinically relevant anti‑aging ocular effect.
- Efficacy of anti-aging products for periorbital wrinkles as measured by 3-D imaging
PubMed ID: 19735523
Topical carnosine-containing formulations reduced wrinkle roughness over 4 weeks—cosmetic anti-aging effect (surface-level).
- l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial
PubMed ID: 29420997
Reduction of AGEs and inflammation in T2D relates to mechanisms of aging; direct anti‑aging claims are inferential but plausible.
- Efficacy of N-acetylcarnosine in the treatment of cataracts
PubMed ID: 12001824
Randomized NAC trial showed objective improvements in lens imaging and function consistent with anti‑aging effects on the eye.
Blood circulation (4)
- Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure
PubMed ID: 25287762
L‑carnosine added to usual therapy in chronic HF improved 6MWT and peak VO2, reflecting improved functional circulation/exercise capacity.
- Carnosine-enriched functional food enhances micro- and macrovascular endothelium-independent vasodilation in competitive athletes-a randomized study
PubMed ID: 39983097
Directly demonstrated increased micro- and macrovascular vasodilation and reduced BP in healthy male athletes.
- Beneficial effect of polaprezinc on cardiac function post-myocardial infarction: A prospective and randomized clinical trial
PubMed ID: 30855449
Polaprezinc after MI associated with greater EF recovery—direct circulation/functional cardiac improvement.
- Effects of α-Lipoic Acid, Carnosine, and Thiamine Supplementation in Obese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind Study
PubMed ID: 30311825
Combination supplement (ALA+carnosine+thiamine) lowered glucose and improved metabolic markers that can favor circulation; multi‑ingredient caveat.
Heart health (4)
- Beneficial effect of polaprezinc on cardiac function post-myocardial infarction: A prospective and randomized clinical trial
PubMed ID: 30855449
Polaprezinc post‑MI trial showed greater EF improvement and reduced inflammation index—strong CV signal.
- l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial
PubMed ID: 29420997
L‑carnosine lowered triglycerides and improved body composition in T2D—favorable for cardiovascular risk though not direct CV outcome data.
- Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure
PubMed ID: 25287762
L‑carnosine improved functional exercise capacity and peak VO2 in chronic heart failure—supportive for cardiovascular function.
- Carnosine-enriched functional food enhances micro- and macrovascular endothelium-independent vasodilation in competitive athletes-a randomized study
PubMed ID: 39983097
Direct, clinically relevant vascular improvements (vasodilation, lower BP) in healthy athletes support cardiovascular endpoints.
Stress resilience (2)
- L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial
PubMed ID: 32063564
Adjunctive benefit in depression may reflect improved psychological stress coping/resilience.
- L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways
PubMed ID: 30592963
Reduced oxidative/inflammatory mediators and milder neuropathy suggest improved resilience to chemo stress.
Mood balance (2)
- L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial
PubMed ID: 32063564
Adjunctive carnosine with citalopram produced greater HAM‑D reduction and higher response/remission (RCT).
- L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study
PubMed ID: 28485008
Adjunct L-carnosine reduced OCD symptom severity when added to SSRI, indicating psychiatric/mood-related benefit in that disorder.
Muscle maintenance (2)
- A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial
PubMed ID: 38732615
Multi‑ingredient supplement including carnosine produced clinically meaningful increases in muscle mass and strength in sarcopenic older adults.
- The effects of beta-alanine supplementation on physical working capacity at heart rate threshold
PubMed ID: 24308676
28 days β-alanine increased PWC at HR threshold (work-capacity measure) vs placebo; mixed effects on other endpoints.
Workout performance (2)
- Carnosine-enriched functional food enhances micro- and macrovascular endothelium-independent vasodilation in competitive athletes-a randomized study
PubMed ID: 39983097
Study in athletes with improved vascular function and reduced BP—findings are directly relevant to athletic performance potential though sample/scope are limited.
- The effects of beta-alanine supplementation on physical working capacity at heart rate threshold
PubMed ID: 24308676
Higher PWC(HRT) (work at a given HR) after 28 days β-alanine indicates improved functional athletic capacity.
Energy & Fatigue (1)
- Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure
PubMed ID: 25287762
L‑carnosine improved 6MWT and peak VO2 in HF patients, indicating increased physical energy/exercise capacity.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Carnosine
Search all237 products whose verified label declares Carnosine — not every bottle that mentions it in a title.